Bone Biologics grants director 113,896 stock options

Q: How many BBLG options did director Siddhesh Rajendra Angle receive?

Siddhesh Rajendra Angle received 113,896 non-employee stock options on September 28, 2026, with a $0.50 exercise price and a September 28, 2036 expiration date.

A separate existing option covers 10,483 common shares at a $5.28 exercise price and expires June 4, 2035.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Bone Biologics Corp director Siddhesh Rajendra Angle received a grant of 113,896 non-employee stock options on September 28, 2026. The options have a $0.50 exercise price and expire September 28, 2036. The award was made under Bone Biologics Corporation's 2015 Equity Incentive Plan and described as exempt under Rule 16b-3.

Insider Trade Summary

Grant/Award: 113,896 shares

Grant/Award 8 txns

Insider Angle Siddhesh Rajendra

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Non-Employee Stock Option ^F1	113,896	$0.00	$0.00
holding	Non-Employee Stock Option ^F2	--	--	--
holding	Non-Employee Stock Option ^F2	--	--	--
holding	Non-Employee Stock Option ^F2	--	--	--
holding	Non-Employee Stock Option ^F2	--	--	--
holding	Non-Employee Stock Option ^F2	--	--	--
holding	Non-Employee Stock Option ^F2	--	--	--
holding	Non-Employee Stock Option ^F2	--	--	--

Holdings After Transaction: Non-Employee Stock Option — 131,334 contracts for 17,438 underlying shares (Direct)

Footnotes (2)

F1. This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.
F2. This option is fully exercisable as of the date of this report.

Key Figures

Options granted: 113,896 options Exercise price: $0.50 per share Expiration date: September 28, 2036 +2 more

5 metrics

Options granted 113,896 options Granted September 28, 2026; underlying security is Common Stock

Exercise price $0.50 per share Newly granted options

Expiration date September 28, 2036 Newly granted options

Existing option underlying shares 10,483 shares Direct option; $5.28 exercise price; expires June 4, 2035; fully exercisable as of the report date

Existing option underlying shares 5,119 shares Direct option; $10.38 exercise price; expires September 17, 2034; fully exercisable as of the report date

Key Terms

Non-Employee Stock Option, 2015 Equity Incentive Plan, Rule 16b-3, fully exercisable

4 terms

Non-Employee Stock Option financial

"This option was granted"

2015 Equity Incentive Plan financial

"under the Bone Biologics Corporation 2015 Equity Incentive Plan"

Rule 16b-3 regulatory

"transaction exempt under Rule 16b-3"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

fully exercisable financial

"This option is fully exercisable"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BBLG options did director Siddhesh Rajendra Angle receive?

Siddhesh Rajendra Angle received 113,896 non-employee stock options on September 28, 2026, with a $0.50 exercise price and a September 28, 2036 expiration date.

How do Siddhesh Rajendra Angle's BBLG options vest?

Except as otherwise provided in the award notice, the options vest in four equal quarterly installments. They were granted under Bone Biologics Corporation's 2015 Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/30/2026 - 05:13 PM Accepted by SEC EDGAR 09/30/2026 - 05:12 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Angle Siddhesh Rajendra

(Last)

(First)

(Middle)

C/O BONE BIOLOGICS CORP

2 BURLINGTON WOODS DR. SUITE 100

(Street)

BURLINGTON

MASSACHUSETTS

01803

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bone Biologics Corp [ BBLG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Employee Stock Option	$0.5	09/28/2026		A		113,896		⁽¹⁾	09/28/2036	Common Stock	113,896	$0	113,896	D
Non-Employee Stock Option	$5.28							⁽²⁾	06/04/2035	Common Stock	10,483		10,483	D
Non-Employee Stock Option	$10.38							⁽²⁾	09/17/2034	Common Stock	5,119		5,119	D
Non-Employee Stock Option	$30.72							⁽²⁾	09/13/2033	Common Stock	1,787		1,787	D
Non-Employee Stock Option	$2,323.58							⁽²⁾	08/23/2027	Common Stock	26		26	D
Non-Employee Stock Option	$5,068.8							⁽²⁾	01/01/2032	Common Stock	7		7	D
Non-Employee Stock Option	$7,560							⁽²⁾	10/26/2031	Common Stock	3		3	D
Non-Employee Stock Option	$7,560							⁽²⁾	10/15/2031	Common Stock	13		13	D

Explanation of Responses:

1. This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests infour equal quarterly installments.

2. This option is fully exercisable as of the date of this report.

	/s/ Siddhesh Angle	09/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR